Kandzari, D. E., Tcheng, J. E., Grines, C. L., Effron, M., Cox, D. A., Garcia, E., … Stone, G. W. (2003). Benefits and risks of abciximab use in primary Angioplasty for acute myocardial infarction: The CADILLAC trial. In JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (Vol. 41, pp. 357A-357A). CHICAGO, ILLINOIS: ELSEVIER SCIENCE INC.

Kandzari, D. E., J. E. Tcheng, C. L. Grines, M. Effron, D. A. Cox, E. Garcia, J. J. Griffin, et al. “Benefits and risks of abciximab use in primary Angioplasty for acute myocardial infarction: The CADILLAC trial.” In JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 41:357A-357A. ELSEVIER SCIENCE INC, 2003.

Kandzari DE, Tcheng JE, Grines CL, Effron M, Cox DA, Garcia E, et al. Benefits and risks of abciximab use in primary Angioplasty for acute myocardial infarction: The CADILLAC trial. In: JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY. ELSEVIER SCIENCE INC; 2003. p. 357A-357A.

Kandzari, D. E., et al. “Benefits and risks of abciximab use in primary Angioplasty for acute myocardial infarction: The CADILLAC trial.” JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, vol. 41, no. 6, ELSEVIER SCIENCE INC, 2003, pp. 357A-357A.

Kandzari DE, Tcheng JE, Grines CL, Effron M, Cox DA, Garcia E, Griffin JJ, Guagliumi G, Stuckey TD, Turco M, Lansky AJ, Mehran R, Stone GW. Benefits and risks of abciximab use in primary Angioplasty for acute myocardial infarction: The CADILLAC trial. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY. ELSEVIER SCIENCE INC; 2003. p. 357A-357A.